Orchestra BioMed Receives US FDA Approval for Heart Device Trial
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $118
Nephron Research Adjusts Boston Scientific Price Target to $125 From $120
Boston Scientific Hits 4-week High
The Return Trends At Boston Scientific (NYSE:BSX) Look Promising
America Inc. Slashes Spending as Tariff Uncertainty Swirls -- WSJ
Executive Reshuffles: NNDM, BSX, and APPN
Headache For MOH With Trump's Flip-Flop On Pharma Tariff
A Quick Look at Today's Ratings for Boston Scientific(BSX.US), With a Forecast Between $110 to $125
Boston Scientific Is Maintained at Overweight by Barclays
Boston Scientific Corporation Just Beat EPS By 7.3%: Here's What Analysts Think Will Happen Next
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Encompass Health (EHC) and Integer Holdings (ITGR)
The company's CEO has clearly stated: the trade war will destroy everything!
Due to the cost surge brought about by Trump's tariff policy and the wavering of Consumer confidence, many corporate giants in the USA have significantly lowered their earnings expectations during this earnings report season, covering various fields such as Consumer goods, Aviation, Energy, and telecommunications. Statistics show that more than 90% of companies mentioned the impact of tariffs during their earnings call, with the mention rate of the term 'recession' soaring from less than 3% in the fourth quarter of last year to 44%.
Boston Scientific Has Positive Farapulse, Farapoint Data
Express News | Second Phase of Advantage Af Study of Farapulse™ Pulsed Field Ablation System Meets Primary Safety and Efficacy Endpoints
Second Phase of ADVANTAGE AF Study of FARAPULSE Pulsed Field Ablation System Meets Primary Safety and Efficacy Endpoints
Express News | Needham Maintains Buy on Boston Scientific, Raises Price Target to $115
Barclays Raises Price Target on Boston Scientific to $125 From $118
Boston Scientific (NYSE:BSX) Announces CFO Retirement And Strong Earnings Growth
Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results